[2016 - 2018年台州市新报告艾滋病病毒/艾滋病患者在接受抗逆转录病毒治疗前的艾滋病病毒1型耐药性及亚型分析]

[HIV-1 drug resistance and subtypes in newly reported HIV/AIDS patients before antiretroviral therapy in Taizhou city, 2016-2018].

作者信息

Xu L L, Shen W W, Chen X X, Li G X, Xu Y Y, Gao M Y, Zhou S J, Lin H J, He N

机构信息

Department of Epidemiology, School of Public Health, Key Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai 200032, China.

Taizhou City Center for Disease Control and Prevention, Taizhou 318000, China.

出版信息

Zhonghua Liu Xing Bing Xue Za Zhi. 2021 Apr 10;42(4):711-715. doi: 10.3760/cma.j.cn112338-20200706-00926.

DOI:10.3760/cma.j.cn112338-20200706-00926

PMID:34814456

Abstract

To explore the HIV-1 drug resistance and subtypes in newly reported HIV/AIDS patients before antiretroviral therapy (ART) in Taizhou city. A cross-sectional study of HIV-1 drug resistance was conducted among newly reported HIV/AIDS patients before ART in Taizhou from January 2016 to December 2018. HIV-1 gene sequences were obtained by RT-PCR. The sequences were submitted to the Stanford University drug resistance database. The drug resistance mutation and the sensitivity of HIV-1 strains to antiretroviral drugs were determined according to WHO Guidelines on HIV drug resistance surveillance of 2014. A total of 806 HIV-1 gene sequences were obtained successfully. The overall HIV-1 drug resistance rate was 2.9% (23/806), 1.9% for non-nucleoside reverse transcriptase inhibitors (NNRTIs), 0.6% for nucleoside reverse transcriptase inhibitors (NRTIs), and 0.0% for protease inhibitors (PIs), respectively. From 2016 to 2018, the HIV-1 drug resistance rate was 1.6%, 1.8%, and 4.8%, respectively. The resistance mutations of NNRTIs and NRTIs were mainly K103 N (0.7%) and M184I/V (0.5%). HIV-1 subtypes were mostly CRF01_AE (42.7%,344/806),CRF07_BC (28.9%,233/806) and CRF08_BC (11.2%,90/806).HIV-1 subtypes among homosexually transmitted infections were mostly CRF01_AE (53.3%, 136/255) and CRF07_BC (32.2%, 82/255), and HIV-1 subtypes among heterosexually transmitted infections were mainly CRF01_AE (37.7%, 203/539), CRF07_BC (27.5%, 148/539) and CRF08_BC (16.1%, 87/539). HIV-1 drug resistance rate among newly reported HIV/AIDS patients before ART remained low in Taizhou during 2016 to 2018, an increasing trend seemed to be notifiable and warrants continuous surveillance of HIV-1 drug resistance.

摘要

探索台州市新报告的未接受抗逆转录病毒治疗（ART）的HIV/AIDS患者中HIV-1的耐药情况及亚型。对2016年1月至2018年12月台州市新报告的未接受ART的HIV/AIDS患者进行HIV-1耐药情况的横断面研究。通过逆转录聚合酶链反应（RT-PCR）获得HIV-1基因序列。将序列提交至斯坦福大学耐药数据库。根据2014年世界卫生组织HIV耐药监测指南确定HIV-1毒株的耐药突变及对抗逆转录病毒药物的敏感性。共成功获得806条HIV-1基因序列。总体HIV-1耐药率为2.9%（23/806），非核苷类逆转录酶抑制剂（NNRTIs）耐药率为1.9%，核苷类逆转录酶抑制剂（NRTIs）耐药率为0.6%，蛋白酶抑制剂（PIs）耐药率为0.0%。2016年至2018年，HIV-1耐药率分别为1.6%、1.8%和4.8%。NNRTIs和NRTIs的耐药突变主要为K103N（0.7%）和M184I/V（0.5%）。HIV-1亚型主要为CRF01_AE（42.7%，344/806）、CRF07_BC（28.9%，233/806）和CRF08_BC（11.2%，90/806）。经同性传播感染的HIV-1亚型主要为CRF01_AE（53.3%，136/255）和CRF07_BC（32.2%，82/255），经异性传播感染的HIV-1亚型主要为CRF01_AE（37.7%，203/539）、CRF07_BC（27.5%，148/539）和CRF08_BC（16.1%，87/539）。2016年至2018年台州市新报告的未接受ART的HIV/AIDS患者中HIV-1耐药率仍较低，但呈上升趋势，值得对HIV-1耐药情况进行持续监测。